Rocket Lab (RKLB) Stock Tumbles 6% Following $3B Equity Program Announcement

Key Takeaways

• RKLB shares declined 6.34% following the announcement of a $3 billion at-the-market equity offering, sparking concerns over potential shareholder dilution
• Profit-taking intensified after Rocket Lab’s recent inclusion in the Nasdaq-100 index
• First quarter revenue reached $200.35 million, representing a 63.4% annual increase and surpassing analyst expectations of $189.65 million
• Wall Street maintains a Moderate Buy rating with a consensus price target of $102.76; Deutsche Bank increased its forecast to $120
• BI Asset Management significantly reduced its stake by 79.7% during Q1, offloading 122,417 shares

Shares of Rocket Lab (RKLB) experienced a 6.34% decline on Tuesday, starting the session at $95.12, as the market absorbed news of the aerospace company’s planned $3 billion at-the-market equity offering.

Rocket Lab USA, Inc., RKLB

The announcement rattled investors. These at-the-market programs enable companies to issue new shares incrementally over time, and market participants viewed this development as an indication that leadership intends to pursue capital raising — potentially watering down current shareholder stakes.

The aerospace firm had been performing strongly prior to the selloff. RKLB has climbed 36.35% since the start of the year and recently touched a 12-month peak of $151.00, suggesting that portion of Tuesday’s downturn stemmed from investors securing gains following the impressive advance.

The company’s Nasdaq-100 inclusion, initially viewed as a positive development, ultimately became a classic sell-the-news scenario. This pattern frequently emerges — equities typically appreciate leading up to index additions before retreating once the event materializes.

Sector dynamics are playing a role as well. SpaceX’s recent public market entry has captured investor interest and redirected capital flows within the space industry, somewhat diminishing Rocket Lab’s momentum.

First Quarter Performance Exceeded Expectations

Several weeks back, Rocket Lab delivered its most impressive quarterly sales figures on record. First quarter revenue totaled $200.35 million, marking a 63.4% surge compared to the prior-year period and easily surpassing the consensus forecast of $189.65 million.

Earnings per share landed at -$0.07, matching analyst projections and showing improvement from the -$0.12 reported in Q1 2025. The enterprise continues to post a negative net margin of 26.87% alongside a negative return on equity of 11.72%.

Analysts project full-year EPS of -$0.29. While Rocket Lab demonstrates rapid expansion, profitability remains elusive.

Wall Street Price Targets Stay Optimistic

The analyst community hasn’t abandoned its positive stance. Deutsche Bank elevated its price objective from $73 to $120 in May, maintaining its Buy recommendation. Roth MKM boosted its target from $90 to $100, also with a Buy rating. Cantor Fitzgerald reaffirmed its Overweight stance in late May.

The average forecast among 21 analysts stands at Moderate Buy, with a mean price target of $102.76 — positioned above current trading levels.

Not all observers share this optimism. Wells Fargo launched coverage with an Equal Weight designation and a $60 price objective, while BTIG Research maintains a Hold recommendation.

Regarding institutional positioning, BI Asset Management dramatically trimmed its RKLB holdings by 79.7% in Q1, disposing of 122,417 shares and reducing its stake to merely 31,259 shares valued at approximately $2 million. Conversely, Vanguard Group expanded its position by 13.4% in Q4, accumulating 5.6 million additional shares. Institutional investors collectively control 71.78% of outstanding shares.

Insider transactions merit attention as well. CFO Adam Spice divested 62,744 shares at an average price of $142.57 in late May, while insider Frank Klein sold 44,390 shares at the identical price point. Both transactions occurred through pre-established 10b5-1 trading arrangements designed to satisfy tax liabilities associated with vesting equity compensation.

RKLB currently trades beneath its 50-day moving average of $106.79 while maintaining a position well above its 200-day average of $84.38.

The post Rocket Lab (RKLB) Stock Tumbles 6% Following $3B Equity Program Announcement appeared first on Blockonomi.